Welcome to our dedicated page for Nanoviricides news (Ticker: NNVC), a resource for investors and traders seeking the latest updates and insights on Nanoviricides stock.
NanoViricides, Inc. develops clinical-stage antiviral therapeutics based on its nanoviricide technology and host-mimetic nanomedicine approach. Company news centers on NV-387, its lead broad-spectrum antiviral candidate, including clinical development for MPox, respiratory viral infections, measles and other viral diseases, as well as manufacturing updates for clinical product forms such as NV-387 Oral Gummies.
Recurring updates also cover FDA orphan-drug designation activity, rare-disease regulatory strategy, investor-conference participation and the company’s relationship with TheraCour Pharma for antiviral drug development technology. The news flow is focused on antiviral pipeline progress, regulatory designations and disease-area positioning rather than commercial product sales.
NanoViricides, Inc. (NNVC) will present at the LD 500 investor conference on September 3, 2020, at 8:20 AM PDT. The company reports significant advancements in its COVID-19 drug development, claiming efficacy against various coronaviruses, with safe results in animal studies. They are drafting an Investigational New Drug (IND) application to the FDA and intend to re-engage in clinical trials for their shingles drug, NV-HHV-101, targeting a billion-dollar market. Their nanoviricide technology aims to effectively treat enveloped viral infections by mimicking cell surfaces.